within Pharmacolibrary.Drugs.ATC.S;

model S01EE01
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 6.666666666666667e-06,
    adminDuration  = 600,
    adminMass      = 0.05 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01EE01</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Latanoprost is a prostaglandin F2α analogue used primarily for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is an ophthalmic solution administered as one drop in the affected eye(s) once daily. It is widely approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after topical ocular administration.</p><h4>References</h4><ol><li><p>Halder, A, &amp; Khopade, AJ (2021). Pharmacokinetics and Pharmacology of Latanoprost 0.005% without Benzalkonium Chloride Vs Latanoprost 0.005% with Benzalkonium Chloride in New Zealand White Rabbits and Beagles. <i>Current eye research</i> 46(7) 1031–1037. DOI:<a href=\"https://doi.org/10.1080/02713683.2020.1855660\">10.1080/02713683.2020.1855660</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33719796/\">https://pubmed.ncbi.nlm.nih.gov/33719796</a></p></li><li><p>Herceg, M, &amp; Noecker, R (2008). Travoprost/timolol fixed combination. <i>Expert opinion on pharmacotherapy</i> 9(6) 1059–1065. DOI:<a href=\"https://doi.org/10.1517/14656566.9.6.1059\">10.1517/14656566.9.6.1059</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18377347/\">https://pubmed.ncbi.nlm.nih.gov/18377347</a></p></li><li><p>Sjöquist, B, &amp; Stjernschantz, J (2002). Ocular and systemic pharmacokinetics of latanoprost in humans. <i>Survey of ophthalmology</i> 47 Suppl 1 S6–S12. DOI:<a href=\"https://doi.org/10.1016/s0039-6257(02)00302-8\">10.1016/s0039-6257(02)00302-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12204697/\">https://pubmed.ncbi.nlm.nih.gov/12204697</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01EE01;
